Diagnostics

A*STAR researchers devise a new streamlined method for analysing thousands of genes at once on a tissue-wide scale, offering a more accessible tool to study and diagnose diseases at a cellular level.

A*STAR researchers create a next-generation, ultrasensitive COVID-19 rapid test powered by gold nanoparticles.

Asian patients with suspected but undiagnosed rare genetic diseases could get answers sooner thanks to next-generation sequencing technologies.

These novel immune signatures identify patients most at risk for developing severe COVID-19 symptoms.

Using flow cytometry, researchers have developed a sensitive and specific test for COVID-19 that can identify asymptomatic carriers.

Serology testing may be fast and easy to perform, but there are still some limitations that need to be overcome, suggests Laurent Renia.

A new test manufactured by A*STAR’s Diagnostics Development Hub in partnership with Duke-NUS Medical School could reveal if an individual is likely immune to COVID-19.

A biosensor designed with quantum properties is 15 times more sensitive than classical sensors.

In a display of scientific willpower, A*STAR researchers developed and deployed the COVID-19 diagnostic Fortitude Kit within weeks of the virus reaching Singapore’s shores.

Jingmei Li is developing a risk scoring system for breast cancer that could help clinicians formulate better screening programs to catch the disease in its early stages.

A*STAR researchers have devised a method that can detect and distinguish closely related flaviviruses with 100 percent accuracy.

Proteomics expert Ruedi Aebersold discusses the use of multiplex targeted mass spectrometry for one-shot flavivirus diagnosis.